Other

Cv Therapeutics, Inc.

Monsanto Company

Zomanex, LLC

C.v. Therapeuctics

Moore, William M.

Spilburg, Curtis a.

Curtis A Spilburg

Louis G Lange, Iii

Dayton T Reardan

William M Moore

Paula M Kinnunen

Esam Z Dajani

James M Schuck

Louis G Lange

Louis George Lance, Iii

Louis George Iii Lange

A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.

Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs

This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

Method and composition for inhibiting cholesterol esterase

A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.

Method and composition for inhibiting human cholesterol esterase

The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Mammalian pancreatic cholesterol esterase

Peptides from mammalian pancreatic cholesterol esterase

This invention encompasses methods for inhibiting and/or treating gastric and duodenal ulcers by the administration of purified, high molecular weight sulfated polysaccharide compositions.

Method of treating ulcers with sulfated polysaccharides

DNA encoding bovine pancreatic cholesterol esterase

This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Use of non-absorbable synthetic sulfated polysaccharides to decrease

Method of manufacturing non-absorbable synthetic sulfated polysaccharides

Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme. A method for recovering a solution of purified human pancreatic cholesterol esterase having a molecular weight of about 100,000 daltons is disclosed. The 100,000 dalton fraction of human pancreatic cholesterol esterase is purified first, by preparing a solution of dialyzed human pancreatic cytosol containing the esterase and other proteins. Next, the solution is passed over a hydroxyapetite column and then eluted to yield all of the molecular weight fractions of the esterase and other proteins in the solution present as a single peak to give a first eluent. Thirdly, the solution is then passed over a gel filtration column and the esterase is collected as a single peak to give a second eluent including the esterase and protein impurities. Next, the second eluent is dialyzed and then it is passed over a chromatography column containing a chromatography material including heparin agarose and heparin-Sepharose, and then finally washing the column and collecting a third eluent which contains the purified esterase.

Method for recovering purified 100,000 dalton molecular weight fraction

Pancreatic cholesterol esterase inhibitor

Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme.

Method for recovering purified 100,000 molecular weight fraction of

A method for recovering a purified 52,000 dalton fraction of human pancreatic cholesterol esterase is disclosed. The 52,000 dalton fraction of human pancreatic cholesterol esterase is purified by passing a solution having a pH of about 8.2 which contains two or more fractions of human pancreatic cholesterol esterase including the 52,000 dalton fraction over DEAE-cellulose to produce an effluent containing said 52,000 dalton fraction. Since the 52,000 dalton fraction of the esterase does not bind to the DEAE-cellulose whereas the other esterase fractions do bind to the DEAE-cellulose, the 52,000 dalton fraction is then collected in the effluent. The method can be further carried out by passing the purified 52,000 dalton fraction over both hydroxyapatite and heparin-Sepharose to obtain a homogeneous solution of the 52,000 dalton fraction.

Method for recovering purified 52,000 dalton fraction of human

The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quanities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Growing community of inventors

Chesterfield, MO, United States of America

Curtis A Spilburg